FluxMPS™ Minimum Essential Medium (MEM), Low Glucose & 25mM HEPES w/o L-Glutamine, Sodium Pyruvate, Phenol Red: 1X Liquid

FluxMPS™ Minimum Essential Medium (MEM), Low Glucose & 25mM HEPES w/o L-Glutamine, Sodium Pyruvate, Phenol Red: 1X Liquid

FluxMPS™ Minimum Essential Medium (MEM), Low Glucose & 25mM HEPES w/o L-Glutamine, Sodium Pyruvate, Phenol Red: 1X Liquid is a Microfluidics Suitable, quadruple-stage ultra-filtered (0.1 µm ×2 + 0.04 µm ×2) 1X liquid cell culture medium engineered for organ-on-a-chip (OoC), tissue-on-a-chip (ToC), and microphysiological system (MPS) applications. The low-glucose MEM base is HEPES-buffered at 25 mM for stable pH control across open-system culture formats, delivering microchannel-safe purity from the first drop.

• Low-glucose MEM base (1.0 g/L D-glucose) with 25 mM HEPES buffering for reduced CO₂ dependency
• Formulated without L-glutamine, sodium pyruvate, or phenol red — supplement per protocol before use
• Quadruple-stage filtration: 0.1 µm (Prefiltration I & II) + 0.04 µm (Final filtration I & II — Polish)
• Endotoxin release specification: < 0.05 EU/mL (LAL, USP <85> BET), tested per manufacturing batch
• Manufactured under an ISO 13485:2016 quality management system; final QC and packaging at Diagnocine, Totowa, NJ
• pH 7.4 (USP <791>); osmolality reported per Certificate of Analysis (USP <785>)
• Sodium bicarbonate present (2200 mg/L) alongside HEPES for a dual-buffered pH-stability system
• Custom formulations available — pH, glucose, salts, HEPES, and nutrient composition on request

Engineered where standard media fails

Conventional 0.22 µm-filtered media carry mycoplasma-sized particulates (0.2–0.3 µm), subvisible debris, and batch-to-batch endotoxin variation that accumulate inside microchannels — corrupting biosensor readings and shortening device lifetimes. FluxMPS™ is built to reduce these risks at the source.

Quadruple-stage filtration system

FluxMPS™ Minimum Essential Medium (MEM), Low Glucose & 25mM HEPES w/o L-Glutamine, Sodium Pyruvate, Phenol Red: 1X Liquid is processed through a four-stage filtration train — two dedicated 0.1 µm/0.04 µm prefilter-and-final-filter pairs run in series — reaching a 0.04 µm final cut-off well below the mycoplasma size range that 0.22 µm filtration cannot address.

1. 1

   0.1 µm Prefiltration I

   Removes large particulates, cell debris and protein aggregates; protects the first 0.04 µm cartridge.

2. 2

   0.04 µm Final filtration I

   First 0.04 µm pass; retains sub-micron particulates and microaggregates that pass through a 0.22 µm filter.

3. 3

   0.1 µm Prefiltration II

   Second dedicated prefilter protecting the second 0.04 µm cartridge — full redundancy, not a repeat pass.

4. 4

   0.04 µm Final filtration II — Polish

   Ultimate polishing filter; aseptic fill in a validated ISO Class 5 laminar-flow workstation.

Designed for next-generation cell culture platforms

FluxMPS™ Minimum Essential Medium (MEM), Low Glucose & 25mM HEPES w/o L-Glutamine, Sodium Pyruvate, Phenol Red: 1X Liquid is validated for organ-on-a-chip, metabolic research, live-cell imaging, and primary cell models where particulate contamination and endotoxin variation are unacceptable.

Automated Bioreactors & Robotics

An optional 0.01 µm (10 nm) MPS Grade variant — a separate six-stage ultra nano-filtered line — is available for automated bioreactor and robotic perfusion systems requiring the ultimate particulate exclusion.

• Total Particulate Exclusion: 10 nm filtration for nanoscale valve and sensor protection
• Valve & Sensor Protection: reduces particulate-induced blockage risk in precision fluidic systems
• Extended Perfusion Stability: supports flow rate consistency across multi-week automated runs

Inquiry Required: Contact support@diagnocine.com to request the 0.01 µm MPS Grade variant.

Lot-release quality parameters

Every production lot of FluxMPS™ Minimum Essential Medium (MEM), Low Glucose & 25mM HEPES w/o L-Glutamine, Sodium Pyruvate, Phenol Red: 1X Liquid undergoes the complete quality-release battery below before shipment. Available pack sizes: 500 mL, 1000 mL.

Full composition (mg/L)

Complete formulation with CAS numbers, reproduced from manufacturer specification (28 ingredients across 4 categories). Custom compositions available on request.

ISO 13485:2016 manufacturing & compliance

Manufactured under an ISO 13485:2016 QMS with final packaging, testing, and customization at Diagnocine Precision in Totowa, New Jersey, USA.

How DCP-MEMH-QPRN1X (FluxMPS™) compares

Side-by-side comparison against conventional 0.22 µm-filtered alternatives of a similar MEM base formulation.

Comparison figures from published supplier specifications, accessed 2026-09-02. Suppliers that publish no numeric endotoxin specification are shown as "Not specified".

Frequently asked questions

Common questions about FluxMPS™ Minimum Essential Medium (MEM), Low Glucose & 25mM HEPES w/o L-Glutamine, Sodium Pyruvate, Phenol Red: 1X Liquid and Microfluidics Suitable cell culture media.

Supporting literature

Peer-reviewed publications supporting Microfluidics Suitable ultra-filtered media and organ-on-a-chip cell culture applications.

1. Huh D et al. (2010). Reconstituting organ-level lung functions on a chip. Science, 328(5986), 1662–1668. doi:10.1126/science.1188302
2. Bhatia SN & Ingber DE (2014). Microfluidic organs-on-chips. Nature Biotechnology, 32(8), 760–772. doi:10.1038/nbt.2989
3. Eagle H (1959). Amino acid metabolism in mammalian cell cultures. Science, 130(3373), 432–437. doi:10.1126/science.130.3373.432
4. Bhattacharya S et al. (2018). Challenges in maintaining cell viability during microfluidic experiments. Electrophoresis, 39(7), 997–1006. doi:10.1002/elps.201700375
5. Zhang YS et al. (2017). Multisensor-integrated organs-on-chips platform for automated in situ monitoring. PNAS, 114(12), E2293–E2302. doi:10.1073/pnas.1612906114
6. Vernetti L et al. (2017). Functional coupling of human microphysiology systems. Scientific Reports, 7, 42296. doi:10.1038/srep42296
7. Esch EW et al. (2015). Organs-on-chips at the frontiers of drug discovery. Nature Reviews Drug Discovery, 14(4), 248–260. doi:10.1038/nrd4539
8. Zheng F et al. (2021). Organ-on-a-chip systems: microengineering to biomimic living systems. Small, 17(7), 2004175. doi:10.1002/smll.202004175